Autologous Stem Cell Transplantation in Patients with Indolent B Cell Lymphomas in Cuba
Keywords:
indolent B-cell lymphoma; autologous hematopoietic stem cell transplantation; progression-free survival.Abstract
ABSTRACT
Introduction: Indolent B-cell lymphomas are a heterogeneous group of hematological neoplasms. In certain clinical scenarios, autologous hematopoietic stem cell transplantation is a consolidation therapy strategy.
Objective: To evaluate the outcomes obtained in patients with Indolent B-cell lymphomas who underwent autologous hematopoietic stem cell transplantation at the “Hermanos Ameijeiras” Hospital.
Methods: A retrospective study was conducted between 1985 and 2024 in 10 patients with Indolent B-cell lymphomas. Therapeutic response at three months post-transplant, 100-day mortality, causes of death, and five-year progression-free survival were analyzed.
Results: The cohort had a mean age of 40.6 years. The main indication for autologous hematopoietic stem cell transplantation was early relapse. At the time of the procedure, 80% were in complete remission. The most frequently used conditioning regimen included high-dose cyclophosphamide and etoposide, supplemented with total body irradiation (60%). The most commonly used progenitor cell source was bone marrow, stimulated or unstimulated, in equal proportions. Hematologic recovery occurred on average at 13.8 days for neutrophils and 16.6 days for platelets. By three months post-transplant, most patients had achieved complete remission. The main causes of death were relapse/progression and secondary malignancies. No procedure-related mortality was reported in the first 100 days. The estimated five-year progression-free survival rate was 70%.
Conclusions: Autologous hematopoietic stem cell transplantation proved to be a safe and effective procedure in patients with Indolent B-cell lymphomas, confirming its usefulness as a consolidation strategy in the Cuban context.
Downloads
References
1. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720-48. doi: 10.1038/s41375-022-01620-2.
2. Serroukh Y, Montoto S. Indolent Lymphoma. 2024 Apr 11. In: Sureda A, Corbacioglu S, Greco R, Kröger N, Carreras E, editors. The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies [Internet]. 8th ed. Cham (CH): Springer; 2024. Chapter 84. https://doi.org/10.1007/978-3-031-44080-9_84.
3. Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. J Clin Oncol. 2015; 33(23):2516-22. doi: 10.1200/JCO.2014.59.7534.
4. Nizamuddin IA, Bartlett NL. Bispecific antibodies in follicular lymphoma. Haematologica. 2025;110(7):1472-82. doi: 10.3324/haematol.2024.285245.
5. Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055-65. doi: 10.1016/S1470-2045(22)00335-7.
6. Linton KM, Vitolo U, Jurczak W, Lugtenburg PJ, Gyan E, Sureda A, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024;11(8):e593-e605. doi: 10.1016/S2352-3026(24)00166-2.
7. Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9(5):e327-e39. doi: 10.1016/S2352-3026(22)00072-2.
8. Testa U, D'Alò F, Pelosi E, Castelli G, Leone G. CAR-T Cell Therapy for Follicular Lymphomas. Mediterr J Hematol Infect Dis. 2024;16(1):e2024012. doi: 10.4084/MJHID.2024.012.
9. Wang J, Zeng L, Ma X, Xu T, Wu D, Li C. A retrospective cohort study of chimeric antigen receptor T-Cell therapy in follicular lymphoma patients with or without histological transformation. Ann Hematol. 2025;104(6):3309-17. doi: 10.1007/s00277-025-06428-5.
10. Hernández Cruz C. Terapia de células T con receptor quimérico: el desate de las fuerzas de la inmunidad. Acta Médica [Internet]. 19 de mayo de 2025 [citado 13 de marzo de 2026];26. Disponible en: https://revactamedica.sld.cu/index.php/act/article/view/910.
11. Iqbal M, Kumar A, Dreger P, Chavez J, Sauter CS, Sureda AM, et al. Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation. Transplant Cell Ther. 2024; 30(9):832-43. doi: 10.1016/j.jtct.2024.06.025.
12. Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, et al. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2018; 24(6):1163-71. doi: 10.1016/j.bbmt.2017.12.771.
13. Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, et al. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer. 2018;124(12):2541-51. doi: 10.1002/cncr.31374.
14. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-90. https://doi.org/10.1182/blood-2016-01-643569.
15. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31(11):1860-1.
16. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am. 2007;21(5):841-54. https://doi.org/10.1016/j.hoc.2007.06.011.
17. Carnot J, Travieso J, Muñio J, Rodríguez I. Progresos y problemas en el trasplante de médula ósea. Rev Acta Med. 1987;1:180-214.
18. Ruiz Argüelles GJ, Lobato Mendizábal E, Ruiz Argüelles A, Pérez Romano B, Arizpe Bravo D, Marín López A. Non-cryopreserved unmanipulated hematopoietic peripheral blood stem cell autotransplant program: long term results. Arch Med Res. 1999;30(5):380-4. https://doi.org/10.1016/S01880128(99)00042-1.
19. Kaplan EL, Meier P. Non-parametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457.
20. National Cancer Institute. Tratamiento del linfoma no Hodgkin de células B de crecimiento lento (PDQ®)–Versión para profesionales de salud. Bethesda (MD): NCI; 2025 (citado 10/01/26). Disponible en: https://www.cancer.gov.
21. Moreno Nogueira JA, Casas Fernández de Tejerina A, Moreno Rey C. Tratamiento de los linfomas no hodgkinianos indolentes. Rev Clin Esp. 2009;209(2):82-7. doi: 10.1016/S0014-2565(09)70631-9.
22. Smith S. Too much and not enough: revisiting maintenance rituximab in indolent lymphomas. Haematologica. 2022;107(2):353-4. doi: 10.3324/haematol.2021.279101.
23. Li X, Wang X. Effect of POD24 on the prognosis of follicular and other indolent B-cell non-hodgkin lymphomas. Ann Hematol. 2025; 104(3):1427-42. doi: 10.1007/s00277-024-06079-y.
24. Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, Schmitz N, et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia. 2007 ;21(11):2324-31. doi: 10.1038/sj.leu.2404850.
25. Kuruvilla J. The role of autologous and allogeneic stem cell transplantation in the management of indolent B-cell lymphoma. Blood. 2016;127(17):2093-100. doi: 10.1182/blood-2015-11-624320.
26. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86(10):3961-9.
27. Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014; 124(3):344-53. doi: 10.1182/blood-2014-02-514778.
28. Phelan R, Chen M, Bupp C, Bolon YT, Broglie L, Brunner-Grady J, et al. Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. Transplant Cell Ther. 2022; 28(7):409.e1-409.e10. doi: 10.1016/j.jtct.2022.04.012.
29. Dreyling M, Ghielmini M, Rule S, Salles G, Ladetto M, Tonino SH, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):298-308. doi: 10.1016/j.annonc.2020.11.008.
30. Hernández Cruz C, Carnot Uria J, Jorge Muñío Perurena J, García García A, Ríos Jiménez O, Rodríguez Fraga Y. Factores pronósticos del trasplante autólogo en pacientes con Linfoma de Hodgkin. Rev Cubana Med [Internet]. 9 de marzo de 2021 [citado 9 de marzo de 2026];60(3). Disponible en: https://revmedicina.sld.cu/index.php /med/article/view/2515.
31. Ladbury C, Armenian S, Bosworth A, He T, Wong FL, Dandapani S, et al. Risk of Subsequent Malignant Neoplasms Following Hematopoietic Stem Cell Transplantation with Total Body Irradiation or Total Marrow Irradiation: Insights from Early Follow-Up. Transplant Cell Ther. 2022; 28(12):860.e1-860.e6. doi: 10.1016/j.jtct.2022.09.013.
32. Majhail NS. Long-term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2017; 10(4):220-7. doi: 10.1016/j.hemonc.2017.05.009.
33. Metzner B, Pott C, Müller TH, Casper J, Kimmich C, Petershofen EK, et al. Renzelmann A, Rosien B, Thole R, Voß A, Köhne CH, Wellnitz D. Long-term outcome in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation. Eur J Haematol. 2021;107(5):543-552. doi: 10.1111/ejh.13691.
34. Jurinovic V, Metzner B, Pfreundschuh M, Schmitz N, Wandt H, Keller U, et al. Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group. Biol Blood Marrow Transplant. 2018;24(6):1172-9. doi: 10.1016/j.bbmt.2018.03.022.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Calixto Hernández Cruz, José Carnot Uria, Jesús Diego de la Campa, Aliette García García , Jorge Muñío Perurena , Yusaima Rodríguez Fraga , Ibis K. Pardo Ramírez , Kali Cepero Llauger , Mildrey Gutiérrez Izquierdo , Servando Roig Verdecia , Gertrudis Rodríguez Rodríguez , Argelis Cedeño Cedeño , Carlos Pérez Rosales
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
